Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith D Lindor

Showing results (61-70 of 261) with videos related to

Pageof 27
Sort By:
Journal of Hepatology|January 11, 2019
NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A nebulous matterJames H Tabibian, Keith D Lindor
Journal of Clinical Gastroenterology|September 28, 2002
Pregnancy in a patient with primary sclerosing cholangitisAndrea A Gossard, Keith D Lindor
Expert Opinion on Pharmacotherapy|July 29, 2016
Obeticholic acid for the treatment of primary biliary cholangitisAhmad H Ali, Keith D Lindor
Lancet (London, England)|July 11, 2003
Primary biliary cirrhosisJayant A Talwalkar, Keith D Lindor
Expert Opinion on Investigational Drugs|February 16, 2005
Recent advances in the treatment of non-alcoholic fatty liver diseaseFlavia D Mendes, Keith D Lindor
Translational Research : the Journal of Laboratory and Clinical Medicine|February 23, 2010
Is there a role for tetrathiomolybdate in the treatment of primary biliary cirrhosis?Marina G Silveira, Keith D Lindor
Liver International : Official Journal of the International Association for the Study of the Liver|September 12, 2007
Development of autoimmune hepatitis in primary biliary cirrhosisAndrea A Gossard, Keith D Lindor
Hepatology (Baltimore, Md.)|April 23, 2014
Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?)James H Tabibian, Keith D Lindor
Expert Opinion on Investigational Drugs|August 25, 2017
Investigational drugs in phase II clinical trials for primary biliary cholangitisMarina G Silveira, Keith D Lindor
Clinics in Liver Disease|September 28, 2018
Antimitochondrial Antibody-Negative Primary Biliary Cholangitis: Is It Really the Same Disease?David M Chascsa, Keith D Lindor
Pageof 27

Showing results (61-70 of 261) with videos related to

Sort By:
Pageof 27
Journal of Hepatology|January 11, 2019
NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A nebulous matterJames H Tabibian, Keith D Lindor
Journal of Clinical Gastroenterology|September 28, 2002
Pregnancy in a patient with primary sclerosing cholangitisAndrea A Gossard, Keith D Lindor
Expert Opinion on Pharmacotherapy|July 29, 2016
Obeticholic acid for the treatment of primary biliary cholangitisAhmad H Ali, Keith D Lindor
Lancet (London, England)|July 11, 2003
Primary biliary cirrhosisJayant A Talwalkar, Keith D Lindor
Expert Opinion on Investigational Drugs|February 16, 2005
Recent advances in the treatment of non-alcoholic fatty liver diseaseFlavia D Mendes, Keith D Lindor
Translational Research : the Journal of Laboratory and Clinical Medicine|February 23, 2010
Is there a role for tetrathiomolybdate in the treatment of primary biliary cirrhosis?Marina G Silveira, Keith D Lindor
Liver International : Official Journal of the International Association for the Study of the Liver|September 12, 2007
Development of autoimmune hepatitis in primary biliary cirrhosisAndrea A Gossard, Keith D Lindor
Hepatology (Baltimore, Md.)|April 23, 2014
Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?)James H Tabibian, Keith D Lindor
Expert Opinion on Investigational Drugs|August 25, 2017
Investigational drugs in phase II clinical trials for primary biliary cholangitisMarina G Silveira, Keith D Lindor
Clinics in Liver Disease|September 28, 2018
Antimitochondrial Antibody-Negative Primary Biliary Cholangitis: Is It Really the Same Disease?David M Chascsa, Keith D Lindor
Pageof 27